ESR1, CPTAC-145 - CPTAC Assay Portal (original) (raw)
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.
Protein Sequence hover to view complete sequence
CPTAC-145: View additional LLFAPNLLLDR data
CPTAC-1241: View additional LLFAPNLLLDR data
| 10 | 20 | 30 | 40 | 50 |
|---|---|---|---|---|
| MTMTLHTKAS | GMALLHQIQG | NELEPLNRPQ | LKIPLERPLG | EVYLDSSKPA |
| 60 | 70 | 80 | 90 | 100 |
| VYNYPEGAAY | EFNAAAAANA | QVYGQTGLPY | GPGSEAAAFG | SNGLGGFPPL |
| 110 | 120 | 130 | 140 | 150 |
| NSVSPSPLML | LHPPPQLSPF | LQPHGQQVPY | YLENEPSGYT | VREAGPPAFY |
| 160 | 170 | 180 | 190 | 200 |
| RPNSDNRRQG | GRERLASTND | KGSMAMESAK | ETRYCAVCND | YASGYHYGVW |
| 210 | 220 | 230 | 240 | 250 |
| SCEGCKAFFK | RSIQGHNDYM | CPATNQCTID | KNRRKSCQAC | RLRKCYEVGM |
| 260 | 270 | 280 | 290 | 300 |
| MKGGIRKDRR | GGRMLKHKRQ | RDDGEGRGEV | GSAGDMRAAN | LWPSPLMIKR |
| 310 | 320 | 330 | 340 | 350 |
| SKKNSLALSL | TADQMVSALL | DAEPPILYSE | YDPTRPFSEA | SMMGLLTNLA |
| 360 | 370 | 380 | 390 | 400 |
| DRELVHMINW | AKRVPGFVDL | TLHDQVHLLE | CAWLEILMIG | LVWRSMEHPG |
| 410 | 420 | 430 | 440 | 450 |
| KLLFAPNLLL | DRNQGKCVEG | MVEIFDMLLA | TSSRFRMMNL | QGEEFVCLKS |
| 460 | 470 | 480 | 490 | 500 |
| IILLNSGVYT | FLSSTLKSLE | EKDHIHRVLD | KITDTLIHLM | AKAGLTLQQQ |
| 510 | 520 | 530 | 540 | 550 |
| HQRLAQLLLI | LSHIRHMSNK | GMEHLYSMKC | KNVVPLYDLL | LEMLDAHRLH |
| 560 | 570 | 580 | 590 | 595 |
| APTSRGGASV | EETDQSHLAT | AGSTSSHSLQ | KYYITGEAEG | FPATV |
Data source: UniProt
Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs
Uniprot Database Entry PhosphoSitePlus ®
Click a point on a node
to view detailed assay information below
All other points link out to UniProt
Phosphorylation Acetylation Ubiquitylation Other
loading
Assay Details for CPTAC-145 Collapse assay details
Data source: Panorama
Official Gene Symbol
ESR1
Peptide Sequence
LLFAPNLLLDR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
402
Peptide End
412
CPTAC ID
CPTAC-145
Peptide Molecular Mass
1,283.7602
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
cell line lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich
Publication
View Details (opens in a new window)
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV
| n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y9 (1+) | 15.9 | 8.4 | 6.6 | 35.2 | 24.8 | 13.2 | 38.6 | 26.2 | 14.8 | 15 | 15 | 15 |
| y8 (1+) | 19.5 | 10.4 | 6.4 | 48.1 | 25.7 | 10.5 | 51.9 | 27.7 | 12.3 | 15 | 15 | 15 |
| y7 (1+) | 21.9 | 11.1 | 10.6 | 43.6 | 21.9 | 14.5 | 48.8 | 24.6 | 18 | 15 | 15 | 15 |
| sum | 13.8 | 9.4 | 7.2 | 40.4 | 22.8 | 12.5 | 42.7 | 24.7 | 14.4 | 15 | 15 | 15 |
Additional Resources and Comments
Assay Details for CPTAC-1241 Collapse assay details
Data source: Panorama
Official Gene Symbol
ESR1
Peptide Sequence
LLFAPNLLLDR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
402
Peptide End
412
CPTAC ID
CPTAC-1241
Peptide Molecular Mass
1,283.7602
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
Ovarian cancer tumor tissue lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y6 (1+) | 39.7 | 26.4 | 20.9 | 59.9 | 25.9 | 25.4 | 71.9 | 37 | 32.9 | 15 | 15 | 15 |
| y7 (1+) | 6.2 | 6.3 | 5.3 | 45 | 18.6 | 22.2 | 45.4 | 19.6 | 22.8 | 15 | 15 | 15 |
| y8 (1+) | 13.6 | 11.6 | 5.9 | 49 | 19.9 | 24.4 | 50.9 | 23 | 25.1 | 15 | 15 | 15 |
| sum | 7.2 | 7.1 | 5.1 | 45.5 | 17.9 | 22.5 | 46.1 | 19.3 | 23.1 | 15 | 15 | 15 |